Revance Therapeutics Inc (FRA:RTI)
€ 3.4 -0.1 (-2.86%) Market Cap: 371.12 Mil Enterprise Value: 655.05 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 68/100

Revance Therapeutics Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript

Jun 09, 2020 / 07:50PM GMT
Release Date Price: €20 (+2.04%)
Terence C. Flynn
Goldman Sachs Group Inc., Research Division - MD

Great. Thank you. Good afternoon, everybody. I'm Terence Flynn, the GS Biopharma Analyst. Really pleased to have Revance Therapeutics with us. Joining us from the company, we have Mark Foley, who is President and CEO; and Toby Schilke, who is CFO. Thank you very much both for being with us today.

I'm going to turn over to Mark for some brief opening remarks, and then we'll go in to some more questions. But thank you again.

Mark J. Foley
Revance Therapeutics, Inc. - President, CEO & Director

Great. Thanks so much, Terence. My pleasure to be here. These are really exciting times at Revance. As we look to the back half of the year, we're about to embark on 3 significant product launches in aesthetics. We have the RHA filler line that we licensed from TEOXANE for the U.S. market. We have the recently announced HintMD acquisition that is commercial-ready and then we're expecting our BLA approval for our DaxibotulinumtoxinA for Injection November 25 this year. So a big shift from being

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot